Visualitzant Vall d'Hebron Institut d'Oncologia - VHIO per títol
Ara mostrant els elements 765-784 d 869
-
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
(Ferrata Storti Foundation, 2024-02) -
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design
(Future Medicine, 2022-02) -
Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer
(Nature Publishing Group, 2019-09-19) -
Targeting antitumoral proteins to breast cancer by local administration of functional inclusion bodies
(Wiley Online Library, 2019-07-24) -
Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
(MDPI, 2021-08-24) -
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
(American Association for the Advancement of Science, 2022-05-20) -
Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
(Nature Portfolio, 2023-02-15) -
Targeting MYC-driven lymphoma: lessons learned and future directions
(OAE Publishing, 2023-04-12) -
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
(American Association for Cancer Research, 2022-03-15) -
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
(American Medical Association, 2023-09-01) -
TGFβ promotes widespread enhancer chromatin opening and operates on genomic regulatory domains
(Nature Research, 2020-12-03) -
The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways
(Frontiers Media, 2022-02-23)